Roflumilast improves lung function after 6 months compared with placebo

Roflumilast was associated with significant improvements in lung function in patients with moderate and severe chronic obstructive pulmonary disease (COPD) after 6 months of treatment compared with placebo.

Roflumilast is approved to reduce the risk of exacerbations in patients with severe COPD associated with and a history of exacerbations.

To examine the drug's impact on lung function, researchers from multiple institutions, including Baylor College of Medicine; Takeda Pharmaceuticals International GmbH; and Forest Research Institute, randomized 4,746 subjects to roflumilast (pooled intent-to-treat [ITT], n= 2511; moderate COPD, n=1184; severe COPD, n=1217) or placebo (pooled ITT, n=2235; moderate COPD, n=1098; severe COPD, n=1062).

Baseline demographics were similar between treatment groups.

At 6 months, roflumilast increased pre- and postbronchodilator FEV1 by 66 mL and 67 mL, respectively, compared with placebo. Roflumilast, compared with placebo, also increased pre- and postbronchodilator in subjects with moderate and severe COPD.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.


Explore further

Phosphodiesterase 4 inhibitors have only marginal benefits for people with COPD

Citation: Roflumilast improves lung function after 6 months compared with placebo (2012, October 22) retrieved 22 November 2019 from https://medicalxpress.com/news/2012-10-roflumilast-lung-function-months-placebo.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments